Myeloid-derived suppressor cells and plasmacytoid dendritic cells are associated with oncogenesis of oral squamous cell carcinoma.


Journal

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
ISSN: 1600-0714
Titre abrégé: J Oral Pathol Med
Pays: Denmark
ID NLM: 8911934

Informations de publication

Date de publication:
Jan 2023
Historique:
revised: 23 10 2022
received: 26 05 2022
accepted: 03 11 2022
pubmed: 17 11 2022
medline: 10 1 2023
entrez: 16 11 2022
Statut: ppublish

Résumé

Myeloid-derived suppressor cells (MDSCs) help establish the tumor microenvironment by suppressing T-cell response in tumor-bearing hosts. Plasmacytoid dendritic cells (pDCs) activate antigen-specific T cells, thereby, maximizing their antitumor effects. IDO1 is associated with both MDSCs and pDCs and plays a major role in the formation of the tumor-mediated immunosuppressive environment. We utilized immunohistochemistry to examine the involvement of IDO1 in oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs, precancerous lesions). We examined the expression of MDSC markers, CD11b and CD33, as well as pDC markers, CD303 and IDO1, in 60 OSCC and 45 precancerous lesion specimens and analyzed their association with clinicopathological parameters. Expression of these biomarkers identifying MDSCs and pDCs was high in precancerous lesions in patients with severe dysplasia and OSCC. While detecting pDCs, high CD303 and IDO1 expression levels were frequently observed in moderately or poorly differentiated OSCCs. CD11b, CD33, and CD303 levels were significantly correlated with the mode of invasion; CD33 was correlated with OSCC invasion depth while the other three markers tended to be highly expressed in superficial cancer cases showing microinvasion. Expression levels of all four biomarkers were significantly associated with the cancerization of OPMDs to OSCCs. We show, for the first time, that the infiltration of MDSCs and pDCs is significantly associated with progression of premalignant lesions to OSCC. This suggests that these cells may act as prognostic biomarkers for premalignant lesion progression and that immunotherapeutic approaches that control each of these immunosuppressive cells may protect against progression to malignancy.

Identifiants

pubmed: 36380437
doi: 10.1111/jop.13386
pmc: PMC10108148
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9-19

Informations de copyright

© 2022 The Authors. Journal of Oral Pathology & Medicine published by John Wiley & Sons Ltd.

Références

J Immunol. 2006 Jan 1;176(1):284-90
pubmed: 16365420
J Mol Med (Berl). 2012 Nov;90(11):1343-55
pubmed: 22660275
Clin Cancer Res. 2011 Nov 15;17(22):6985-91
pubmed: 22068654
J Clin Oncol. 2007 Jun 20;25(18):2546-53
pubmed: 17577033
Nat Commun. 2019 Nov 27;10(1):5408
pubmed: 31776331
J Immunol. 2008 Oct 15;181(8):5396-404
pubmed: 18832696
Eur J Immunol. 2011 Mar;41(3):749-59
pubmed: 21287554
Int J Cancer. 2017 Mar 1;140(5):1173-1185
pubmed: 27798955
Eur J Cancer Care (Engl). 2010 Nov;19(6):803-8
pubmed: 19702697
Int J Oral Maxillofac Surg. 2019 Oct;48(10):1279-1288
pubmed: 31053518
Head Neck Surg. 1984 May-Jun;6(5):938-47
pubmed: 6724960
Cell Rep. 2015 Oct 13;13(2):412-24
pubmed: 26411680
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Clin Cancer Res. 2005 Aug 15;11(16):6030-9
pubmed: 16115948
Cancer Immunol Res. 2013 Dec;1(6):402-15
pubmed: 24778133
Cancer Metastasis Rev. 2011 Mar;30(1):83-95
pubmed: 21249423
Front Oncol. 2013 Mar 15;3:49
pubmed: 23508517
Clin Rev Allergy Immunol. 2019 Jun;56(3):308-321
pubmed: 28963611
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Cancer Res. 2017 Jan 15;23(2):370-378
pubmed: 27440266
Trends Immunol. 2003 Jun;24(6):302-6
pubmed: 12810105
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
Annu Rev Immunol. 2011;29:163-83
pubmed: 21219184
Clin Cancer Res. 2006 Feb 15;12(4):1144-51
pubmed: 16489067
Front Immunol. 2015 Sep 28;6:493
pubmed: 26441996
J Oral Pathol Med. 2017 Nov;46(10):928-933
pubmed: 28585308
J Immunol. 2009 Jul 15;183(2):937-44
pubmed: 19553533
J Exp Med. 2013 Jul 1;210(7):1389-402
pubmed: 23752227
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
J Oral Pathol Med. 2023 Jan;52(1):9-19
pubmed: 36380437
Cancer Res. 2008 Jul 1;68(13):5439-49
pubmed: 18593947

Auteurs

Atsumu Kouketsu (A)

Division of Oral and Maxillofacial Surgery, Department of Oral Medicine and Surgery, Tohoku University Graduate School of Dentistry, Sendai, Miyagi, Japan.
Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Saito Haruka (S)

Division of Oral Pathology, Department of Oral Medicine and Surgery, Tohoku University Graduate School of Dentistry, Sendai, Miyagi, Japan.

Kanako Kuroda (K)

Division of Oral and Maxillofacial Surgery, Department of Oral Medicine and Surgery, Tohoku University Graduate School of Dentistry, Sendai, Miyagi, Japan.

Miyashita Hitoshi (M)

Division of Oral and Maxillofacial Surgery, Department of Oral Medicine and Surgery, Tohoku University Graduate School of Dentistry, Sendai, Miyagi, Japan.

Yamauchi Kensuke (Y)

Division of Oral and Maxillofacial Surgery, Department of Oral Medicine and Surgery, Tohoku University Graduate School of Dentistry, Sendai, Miyagi, Japan.

Sugiura Tsuyoshi (S)

Division of Oral and Maxillofacial Surgery, Department of Oral Medicine and Surgery, Tohoku University Graduate School of Dentistry, Sendai, Miyagi, Japan.

Tetsu Takahashi (T)

Division of Oral and Maxillofacial Surgery, Department of Oral Medicine and Surgery, Tohoku University Graduate School of Dentistry, Sendai, Miyagi, Japan.

Kumamoto Hiroyuki (K)

Division of Oral Pathology, Department of Oral Medicine and Surgery, Tohoku University Graduate School of Dentistry, Sendai, Miyagi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH